Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclona...
Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx
About this item
Full title
Author / Creator
Publisher
Berlin: Springer
Journal title
Language
English
Formats
Publication information
Publisher
Berlin: Springer
Subjects
More information
Scope and Contents
Contents
In this open uncontrolled phase I study, nine patients with stage III and IV squamous cell carcinoma of the head and neck (SCCHN) were treated with five administrations of the humanized antiepidermal growth factor receptor monoclonal antibody EMD 72000 in three consecutive ascending dose groups. Loading doses of 100 mg (group I), 200 mg (group II),...
Alternative Titles
Full title
Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1007_s002800000270
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1007_s002800000270
Other Identifiers
ISSN
0344-5704
E-ISSN
1432-0843
DOI
10.1007/s002800000270
